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Abstract 
Metastatic germ cell tumours (GCTs) are usually cured with cisplatin based chemother-
apy and standard treatment algorithms are established. However when this treatment 
fails and the disease relapses, standard treatment is much more uncertain. Both conven-
tional dose therapy (CDT) and high dose therapy (HDT) are widely used, due to the lack 
of conclusive data supporting one specific approach. A recent retrospective analysis fo-
cusing on this population suggested a significant benefit for HDT. Retrospective analyses 
are prone to bias, and therefore while this data is provocative it is by no mean conclusive. 
For this reason the international community is supporting a prospective randomised trial 
in this area comparing CDT(TIP) with sequential HDT (TICE). The planned open labelled 
randomised phase III study (TIGER) is due to open in 2011 and will recruit 390 patients to 
detect a 13% difference in 2 year progression free survival (primary endpoint). It is hoped 
that this large study will conclusively resolve the uncertainty which currently exists. 
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Background 
Testicular  cancers  or  germ  cell  tumours  (GCT) 
represent  the  most  common  malignancy  affecting 
adolescent and young adult men in Europe and the 
United States. The peak incidence at approximately 
17/100,000 occurs in the 25-34 age group. Therefore 
GCTs  account  for  the  greatest  average  number  of 
years of life lost of any adolescent or adult malignancy 
[1]. 
The majority of patients with metastatic GCT are 
cured  with  initial  chemotherapy.  This  treatment  is 
well defined and usually consists of cisplatin based 
therapy. However, if the disease relapses, outcomes 
are much less secure and despite further chemother-
apy, the majority of patients die from GCT [2,3].  
Conventional-dose  chemotherapy  (CDCT)  and 
high-dose  chemotherapy  (HDCT)  are  both  used  as 
salvage  treatment  strategies  for  patients  with  meta-
static GCTs who experience progression with or after 
first-line treatment [3,4]. At recent international con-
sensus meetings (G3 testis meeting: ASCO 2010) in-
vestigators agreed that identifying the optimal initial 
salvage approach (CDT vs HDT) is the most pressing 
question remaining in GCTs. 
Evidence for CDCT at relapse 
A  number  of  CDCT  regimens  based  on 
ifosfamide & cisplatin plus vinblastine (VeIP), etopo-
side (IPE or VIP) or paclitaxel (TIP) have been used 
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over  the  last  2  decades  [3,5].  When  considering  all 
relapsed  or  refractory  patients,  complete  response 
(CR) rates of around 50-60% and 2 year PFS of 20-35% 
have been seen [3]. TIP has arguably become the most 
widely accepted CDT regimen over the last 5 years. It 
consists of 4 cycles of paclitaxel ifosfamide and cis-
platin therapy given in 3 weekly intervals with G-CSF 
support. Single arm phase II data supports its use is 
this setting with 2 year PFS figures of approximately 
30% [5].  
Evidence for HDCT at relapse 
GCTs are an ideal model for the study of inten-
sive HDCT. This is because it is associated with a high 
response  rate  to  chemotherapy,  bone  marrow  in-
volvement is extremely rare, patients are young and 
tolerate intensive therapy well, the dose-limiting tox-
icity of known active agents is myelosuppression and 
a dose response relationship has been suggested for 
two  such  agents  (carboplatin  and  etoposide)  [4]. In-
vestigators have therefore used HDCT in an attempt 
to improve outcomes in this setting.  
The  most  robust  single  institution  data  comes 
from Indiana University: 184 consecutive metastatic 
testicular cancer patients were treated with 2 cycles 
(n=173)  or  1  cycle  (n=11)  of  high-dose  etoposide  & 
carboplatin  [6].  During  a  median  follow-up  of  48 
months, 63% of patients achieved a durable remission 
and  5  year  OS  was  approximately  65%11.  This  trial 
excluded some unfavorable groups of patients such as 
those with extragonadal primary tumor sites and late 
relapses. 
The  TI-CE  high-dose  regimen  was  developed 
more recently with the goal of targeting patients with 
an unfavourable prognosis with CDT [7]. TI-CE con-
sists of an initial 2 cycles of rapidly recycled paclitaxel 
and ifosfamide followed by stem cell collection. The 
high dose component of this therapy consists of 3 cy-
cles  of  carboplatin  and  etoposide,  each  supported 
with stem cell infusion (figure 1). In a phase II study 
consisting  of  107  patients,  complete  response  rates 
were high and the 5 year disease free survival was 
47% with an overall survival of 52%. The regimen has 
good  stem  cell  mobilisation  rates  (7/107  patients 
failed to receive any HDCT compared with 13/108 in 
previous studies with other regimens [2].  
Retrospective prognostic factor analysis 
To test the benefit of HDT in comparison CDT 2 
retrospective comparisons have been made. In 2002, 
Beyer et al conducted a retrospective analysis on 55 
matched pairs of pts receiving HDT or CDT [8]. Haz-
ard ratios (HR) favouring HDCT of between 0.72 & 
0.84 for event free survival & between 0.77 & 0.83 for 
OS (depending on the type of analysis) were reported  
Recently  the  International  Prognostic  Factors 
Study  Group  have  reported  retrospective  data  on 
1,594 patients with GCTs treated in the initial salvage 
setting [9,10]. All patients had  experienced progres-
sion after at least 3 and no more than 6 cisplatin-based 
chemotherapy  cycles.  These  patients  were  treated 
with  either  cisplatin-based  CDT  (n=773)  or  car-
boplatin-based HDT (n=821). Data was collected from 
38 centres worldwide. In this non-randomised com-
parison, the HR for PFS was 0.44 (95% CI, 0.39 to 0.51) 
stratified by prognostic category, and for OS was 0.65 
(95% CI, 0.56 to 0.75), favouring HDT. Results were 
consistent  within  each  prognostic  category  except 
among  low-risk  patients,  for  whom  similar  overall 
survival was observed between the two. 
Prospective Randomised Trials in Relapsed 
disease 
Any potential benefit of HDT over CDT should 
be  confirmed  in  a  randomized  trial.  Only  one  such 
trial has been undertaken organised by European in-
vestigators led by French GCT group (GETUG) and 
the  European  Bone  Marrow  transplant 
(NCT00002566) [11]. This study randomised 280 GCT 
patients  who  had  progressed  after  first-line  chemo-
therapy to 4 cycles of CDCT or 3 cycles of the same 
regimen  followed  by  a  single  cycle  of  HDCT  (car-
boplatin, etoposide, & cyclophosphamide), followed 
by autologous bone marrow and/or peripheral blood 
stem  cell  transplantation.  With  45  months  median 
follow-up, no statistically significant differences were 
seen in terms of event-free survival or overall surviv-
al.  There  were  criticisms  of  the  trial  methodology: 
only 98/140 patients randomised to HDCT actually 
received it and there was a higher than expected rate 
of treatment mortality (3% for CDT v 7% for HDT). 
Finally a single cycle rather than sequential cycles of 
HDCT were given. Therefore many believe that the 
trial did not definitively settle the HDCT vs. CDCT 
question resulting in widespread use of HCT. 
Lack of consensus on the treatment of re-
lapsed GCTs? 
The conflict between retrospective and random-
ised data has led to significant heterogeneity of initial 
salvage  treatment  approaches  on  the  local,  regional 
and national levels. The recent retrospective analysis 
of 1594 patients with relapsed disease demonstrated 
the international uncertainty about the optimal initial 
salvage treatment approach, with 52% being treated 
with  CDT  and  48%  receiving  HDT  [10].  Therefore 
when this data was presented at ASCO 2010, the in-
ternational GCT community met and decided a pro- Journal of Cancer 2011, 2 
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spective  study  comparing  CDT  and  HDT  was  the 
most  presenting  question  in  GCTs.  The  TIGER 
(RANDOMIZED  PHASE  III  TRIAL  OF  INITIAL 
SALVAGE  CHEMOTHERAPY  FOR  PATIENTS 
WITH  GERM  CELL  TUMORS)  trial  (PI:  Darren 
Feldman  [MSKCC];  Co-PI:  Robert  Huddart  [Royal 
Marsden] and Thomas Powles (Barts cancer Institute) 
has been specifically designed to address this issue in 
a prospective manner using the most recent and rel-
evant chemotherapy regimens (TIP and TI-CE). The 
trial  will  be  an  international  collaboration  among 
many  centres  across  North  America  (United  States 
and  Canada),  Europe  (UK,  Germany,  France,  Italy, 
Spain, Denmark) and Australia.  
 
 
 
 
Figure 1. Overview of TIGER study summarizing treatment regimens  Journal of Cancer 2011, 2 
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Details of the regimens 
CDCT using the TIP regimen (Control) 
Cycles 1-4 (q21d): Paclitaxel 250mg/m2 IV over 
24 hrs (d1), Ifosfamide 1500mg/m2 IV + mesna sup-
port (d2-5), Cisplatin 25mg/m2 IV (d2-5), Peg-G-CSF 
6mg  SQ  (d6  or  d7)  or  G-CSF  5mcg/kg  (d7-18  or 
ANCR). 
HDCT using TI-CE  
Cycles 1-2 (q14d): Paclitaxel 250mg/m2 IV over 
24hrs (d1), Ifosfamide 2000mg/m2 IV + mesna sup-
port  (d2-4),  G-CSF  10mcg/kg/d  (d4-14),  Stem  cell 
collection (d11-14). 
Cycles 3-5 (q21d): Carboplatin AUC=8 IV (d1-3), 
Etoposide  400mg/m2  IV  (d1-3),  Stem  cell  infusion, 
G-CSF  10mcg/kg/d  (d3-ANCR)  or  Peg-G-CSF  6mg 
SQ once (d5). 
Summary of inclusion criteria of TIGER trial 
Men  over  the  age  of  16  with  confirmed  GCT 
histology will be included in the study. Patients will 
require  unequivocal  progression  of  measurable  dis-
ease after a minimum of 3 and no more than 6 cispla-
tin-based chemotherapy cycles, administered as part 
of first-line (initial) chemotherapy.  
Statistical considerations of the TIGER trial 
The primary endpoint is 2 year progression free 
survival. With 390 patients (248 PFS events) there will 
be 80% power to detect a 13% difference in 2 year PFS 
assuming the 2 year PFS in the control arm (TIP) is 
30%. There will also be 54% to 71% power to detect a 
difference of 12% in 3 year overall survival, the most 
important secondary endpoint of the trial. This value 
will  depend  on  the  3  year  overall  survival  of 
TIP-treated  patients,  which  is  estimated  to  be  50% 
based on the values from the IT94 CDCT arm & the 
large retrospective observational study [5,10]. 
Summary 
The treatment for relapsed GCTs is an area of 
equipoise.  Both  CDCT  and  HDCT  are  widely  used 
and  current  data  potentially  supports  both  ap-
proaches.  The  GCT  community  is  therefore  investi-
gating  this  issue  as  part  of  a  randomised  phase  III 
study comparing TIP and TI-CE.  
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